| abstract |
A chimeric polypeptide comprising a portion of Factor VIII and a distinct portion of Factor VIII, for use in the prevention or treatment of a bleeding episode in a human subject, where the chimeric polypeptide should be administered in a dose of 25 IU / kg at 65 IU / kg at a dosage interval of once every 3 or more days, where the different portion of Factor VIII is a FcRn binding partner (FcRn BP). |